secwatch.observer — SEC 8-K summary
======================================

Issuer:     LeonaBio, Inc. (LONA)
CIK:        0001620463
Form:       8-K
Filed at:   2021-08-16T23:59:59+00:00
Accession:  0001564590-21-044631
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Athira Pharma Q2 net loss $14.0M; advances Alzheimer's trials; open label extension initiated
--------------------------------------------------------------------------------

- Net loss $14.0M ($0.38/sh) vs $2.0M loss in Q2 2020; R&D expenses $12.0M (up from $1.7M).
- Cash and investments $349.9M as of June 30, 2021, up from $268.2M at year-end 2020.
- Open label extension started for LIFT-AD and ACT-AD trials; topline data ACT-AD by H1 2022, LIFT-AD by end 2022.
- Phase 2 trial of ATH-1017 for Parkinson's disease dementia targeted to start by end 2021; IND for ATH-1020 by end 2021.
- COO Mark Litton assumes day-to-day leadership; board chair Tadataka Yamada died; Kelly Romano appointed chair.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1620463/000156459021044631/0001564590-21-044631-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1620463/000156459021044631/atha-8k_20210816.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-044631

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer